Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019095 | 1.00 | KMT2A (0.39) | KMT2AMEN1CCNT1CDK9RORC | |
| SCHEMBL4021029 | 0.92 | KMT2A (0.44) | KMT2AMEN1RORCKDM4EALDH1A1 | |
| SCHEMBL4021027 | 0.92 | KMT2A (0.44) | KMT2AMEN1RORCKDM4EALDH1A1 | |
| SCHEMBL4019987 | 0.90 | KMT2A (0.39) | KMT2AMEN1RORCKDM4EALDH1A1 | |
| SCHEMBL4019982 | 0.90 | KMT2A (0.39) | KMT2AMEN1RORCKDM4EALDH1A1 | |
| SCHEMBL4023783 | 0.89 | KMT2A (0.43) | KMT2AMEN1RORCKDM4EALDH1A1 | |
| SCHEMBL4023780 | 0.89 | KMT2A (0.43) | KMT2AMEN1RORCKDM4EALDH1A1 | |
| SCHEMBL4026443 | 0.84 | TERT (0.40) | KMT2AMEN1RORCALDH1A1 | |
| SCHEMBL4026439 | 0.84 | TERT (0.40) | KMT2AMEN1RORCALDH1A1 | |
| SCHEMBL4025031 | 0.84 | LMNA (0.37) | KMT2AMEN1RORCKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | KMT2A 2820/4885MEN1 77/4885CCNT1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.